Evid Based Complement Alternat Med. 2022 Nov 28;2022:2996878. doi: 10.1155/2022/2996878. eCollection 2022.

NO ABSTRACT

PMID:36479180 | PMC:PMC9722288 | DOI:10.1155/2022/2996878

Clin Rheumatol. 2022 Dec 7. doi: 10.1007/s10067-022-06466-8. Online ahead of print.

NO ABSTRACT

PMID:36477394 | DOI:10.1007/s10067-022-06466-8

Am J Respir Cell Mol Biol. 2022 Dec 7. doi: 10.1165/rcmb.2022-0208TR. Online ahead of print.

NO ABSTRACT

PMID:36476129 | DOI:10.1165/rcmb.2022-0208TR

Cureus. 2022 Nov 4;14(11):e31107. doi: 10.7759/cureus.31107. eCollection 2022 Nov.

NO ABSTRACT

PMID:36475156 | PMC:PMC9719881 | DOI:10.7759/cureus.31107

BMC Pulm Med. 2022 Dec 6;22(1):467. doi: 10.1186/s12890-022-02269-4.

NO ABSTRACT

PMID:36474231 | DOI:10.1186/s12890-022-02269-4

Am J Respir Cell Mol Biol. 2022 Dec 6. doi: 10.1165/rcmb.2022-0203MA. Online ahead of print.

NO ABSTRACT

PMID:36473455 | DOI:10.1165/rcmb.2022-0203MA

Ther Adv Respir Dis. 2022 Jan-Dec;16:17534666221140972. doi: 10.1177/17534666221140972.

NO ABSTRACT

PMID:36468453 | DOI:10.1177/17534666221140972

Front Med (Lausanne). 2022 Nov 16;9:1043720. doi: 10.3389/fmed.2022.1043720. eCollection 2022.

NO ABSTRACT

PMID:36465895 | PMC:PMC9709148 | DOI:10.3389/fmed.2022.1043720

Eur J Med Chem. 2022 Nov 28;246:114953. doi: 10.1016/j.ejmech.2022.114953. Online ahead of print.

NO ABSTRACT

PMID:36463728 | DOI:10.1016/j.ejmech.2022.114953

Respir Med Res. 2022 Nov 30;83:100946. doi: 10.1016/j.resmer.2022.100946. Online ahead of print.

NO ABSTRACT

PMID:36462497 | DOI:10.1016/j.resmer.2022.100946

Int Immunopharmacol. 2022 Dec;113(Pt A):109424. doi: 10.1016/j.intimp.2022.109424. Epub 2022 Nov 8.

NO ABSTRACT

PMID:36461589 | DOI:10.1016/j.intimp.2022.109424

Respir Investig. 2022 Nov 30:S2212-5345(22)00148-4. doi: 10.1016/j.resinv.2022.10.007. Online ahead of print.

NO ABSTRACT

PMID:36460586 | DOI:10.1016/j.resinv.2022.10.007

Eur Rev Med Pharmacol Sci. 2022 Nov;26(22):8411-8424. doi: 10.26355/eurrev_202211_30377.

ABSTRACT

OBJECTIVE: The incidence of idiopathic pulmonary fibrosis is increasing year by year in the world, which has a greater impact on the quality of life of patients. In the past, symptomatic treatment was used in clinical practice, but the overall effect is still not good. Multiple clinical studies have demonstrated the efficacy of pirfenidone in the treatment of idiopathic pulmonary fibrosis; however, adverse reactions have been reported. We, therefore, systematically evaluated the effectiveness and safety of pirfenidone in patients with idiopathic pulmonary fibrosis.

PATIENTS AND METHODS: Relevant studies were retrieved from the Embase, PubMed, Web of Science, Cochrane Library, China National Knowledge Infrastructure (CNKI), Chinese Biomedical Literature (CBM), Wanfang and Weipu databases between January 1999 and May 2020, including the keywords "pirfenidone" and "idiopathic pulmonary fibrosis", were included in our systematic review. Review Manager 5.4 software was used for data synthesis, and analyses of publication bias and sensitivity.

RESULTS: Our systematic review included 13 studies involving a total of 13247 patients with idiopathic pulmonary fibrosis. Pirfenidone was associated with reduced declines in vital capacity (VC) and forced vital capacity (FVC) from baseline in patients with hermansky-pudlak syndrome (HPS)-related pulmonary fibrosis and to moderate idiopathic pulmonary fibrosis (IPF). Pirfenidone treatment was associated with lower reductions in FVC, lower reductions in 6-minute walking test distance, lower decreases in minimum oxygen saturation during the 6-minute walking test, lower all-cause death, lower relative risk of IPF-related death and increased progression-free survival compared to placebo. Progression-free survival was significantly longer in the pirfenidone group. The incidence of gastrointestinal, skin, nervous system, and liver function-related adverse events was significantly higher in the pirfenidone group compared to the control group.

CONCLUSIONS: Pirfenidone has efficacy in delaying the progression of idiopathic pulmonary fibrosis. Pirfenidone is well-tolerated by the majority of patients; however, mild adverse reactions related to the gastrointestinal tract, skin, nervous system, and liver function are common. Overall, Pirfenidone may be an effective and well-tolerated treatment option for idiopathic pulmonary fibrosis.

PMID:36459024 | DOI:10.26355/eurrev_202211_30377

Front Pharmacol. 2022 Nov 15;13:1059434. doi: 10.3389/fphar.2022.1059434. eCollection 2022.

ABSTRACT

Idiopathic pulmonary fibrosis (IPF) is a chronic and lethal lung disease with limited treatment options. The onset of IPF increases with age, indicating that aging is a major risk factor for IPF. Among the hallmarks of aging, cellular senescence is the primordial driver and primary etiological factor for tissue and organ aging, and an independent risk factor for the progression of IPF. In this review, we focus on the senescence of alveolar type II epithelial cells (AECIIs) and systematically summarize abnormal changes in signal pathways and biological process and implications of senescent AECIIs during IPF progression. Meanwhile, we objectively analyze current medications targeting the elimination of senescent cells or restoration of vitality such as senolytics, senomorphics, autophagy regulators, and stem cell therapy. Finally, we dialectically discuss the feasibility and limitation of targeting senescent AECIIs for IPF treatment. We hope that the understanding will provide new insights to the development of senescent AECII-based approaches for the prevention and mitigation of IPF.

PMID:36457712 | PMC:PMC9705785 | DOI:10.3389/fphar.2022.1059434

Cureus. 2022 Oct 30;14(10):e30862. doi: 10.7759/cureus.30862. eCollection 2022 Oct.

ABSTRACT

AIM: Idiopathic pulmonary fibrosis (IPF) is a devastating lung disorder that is characterized by aggressive and dysbalanced wound healing. IPF is mainly a disease of the elderly and thus is likely to share common pathophysiologic mechanisms with other more age-related diseases. Emerging evidence has linked disturbance of sirtuin-1 (SIRT1) expression and activity with aging and diseases of the elderly. In the present study, we aimed to evaluate SIRT1 expression in the peripheral blood mononuclear cells (PBMCs) of patients with IPF given the lack of studies in the literature.

METHODS: We enrolled 34 IPF patients and 22 healthy volunteers (age and sex-matched). In both groups, SIRT1 levels were assessed in plasma, cell pellets of PBMCs, and supernatant from PBMCs' culture with and without the addition of 10% human serum. We also measured transforming growth factor β1 (TGF-β1) concentration in plasma from IPF patients and controls.

RESULTS: The mean (SD) age (years) of the healthy volunteers was 68.57±6.97 and of the IPF patients was 71.28±5.39 years (p>0.05). The mean SIRT1 concentration was found significantly decreased in the supernatant of PBMCs culture (without the addition of serum) in IPF subjects versus controls (1.97±0.59 ng/ml versus 2.40±0.74 ng/ml, respectively, p=0.047). No significant differences were observed between the two groups in the SIRT1 concentration of all the other materials. TGFβ1 concentration of IPF subjects was significantly increased when compared to controls (1281.38±2742.74 versus 131.11±156.06 ng/ml, respectively, p=0.032). Decreased SIRT1 levels in no-serum supernatant were predictive of IPF, after adjustment for age and sex (p=0.014, OR=0.124 [95%CI: 0.023-0.653]).

CONCLUSION: The findings of decreased concentration of SIRT1 in PBMCs supernatant and increased concentration of TGFβ1 in plasma in IPF patients versus controls provide important insights into the role of SIRT1 in IPF and could serve as a tool for the diagnosis and evaluation of patients with IPF.

PMID:36457607 | PMC:PMC9706278 | DOI:10.7759/cureus.30862

BMJ Case Rep. 2022 Dec 1;15(12):e253113. doi: 10.1136/bcr-2022-253113.

NO ABSTRACT

PMID:36455984 | PMC:PMC9716928 | DOI:10.1136/bcr-2022-253113

Respir Med. 2022 Nov 23;205:107060. doi: 10.1016/j.rmed.2022.107060. Online ahead of print.

NO ABSTRACT

PMID:36455497 | DOI:10.1016/j.rmed.2022.107060

Ir J Med Sci. 2022 Dec 1. doi: 10.1007/s11845-022-03241-1. Online ahead of print.

ABSTRACT

BACKGROUND: The SARS-CoV-2 pandemic has prompted clinicians to develop an early and effective treatment of viral infections. To date, vaccines, monoclonal antibodies, and antivirals are the cornerstone of therapy for SARS-CoV-2. AIFA approved the prescription of molnupiravir on 30/12/2021. Molnupiravir is a prodrug that causes the accumulation of errors in the viral genome.

METHODS: We prescribed molnupiravir to a total of 74 patients in a range between 26 and 96 years old and followed-up them for 30 days. 10 patients affected by idiopathic pulmonary fibrosis (IPF) were treated.

RESULTS: The follow-up showed that all of the treated patients presented a regression of symptoms. No patients were hospitalized and/or showed sequelae after the infection by SARS-CoV-2, even though the examined population was older and with more co-morbidities than other patients treated with different antivirals.

CONCLUSION: Molnupiravir is safe and well-tolerated by patients with high-risk of progression to severe COVID. No patients were hospitalized or showed sequelae, including all patients affected by IPF.

PMID:36454535 | DOI:10.1007/s11845-022-03241-1

Elife. 2022 Dec 1;11:e79543. doi: 10.7554/eLife.79543.

ABSTRACT

BACKGROUND: MicroRNAs (miRNA) and other components contained in extracellular vesicles may reflect the presence of a disease. Lung tissue, sputum, and sera of individuals with idiopathic pulmonary fibrosis (IPF) show alterations in miRNA expression. We designed this study to test whether urine and/or tissue derived exosomal miRNAs from individuals with IPF carry cargo that can promote fibrosis.

METHODS: Exosomes were isolated from urine (U-IPFexo), lung tissue myofibroblasts (MF-IPFexo), serum from individuals with IPF (n=16) and age/sex-matched controls without lung disease (n=10). We analyzed microRNA expression of isolated exosomes and their in vivo bio-distribution. We investigated the effect on ex vivo skin wound healing and in in vivo mouse lung models.

RESULTS: U-IPFexo or MF-IPFexo expressed miR-let-7d, miR-29a-5p, miR-181b-3p and miR-199a-3p consistent with previous reports of miRNA expression obtained from lung tissue/sera from patients with IPF. In vivo bio-distribution experiments detected bioluminescent exosomes in the lung of normal C57Bl6 mice within 5 min after intravenous infusion, followed by distribution to other organs irrespective of exosome source. Exosomes labeled with gold nanoparticles and imaged by transmission electron microscopy were visualized in alveolar epithelial type I and type II cells. Treatment of human and mouse lung punches obtained from control, non-fibrotic lungs with either U-IPFexo or MF-IPFexo produced a fibrotic phenotype. A fibrotic phenotype was also induced in a human ex vivo skin model and in in vivo lung models.

CONCLUSIONS: Our results provide evidence of a systemic feature of IPF whereby exosomes contain pro-fibrotic miRNAs when obtained from a fibrotic source and interfere with response to tissue injury as measured in skin and lung models.

FUNDING: This work was supported in part by Lester and Sue Smith Foundation and The Samrick Family Foundation and NIH grants R21 AG060338 (SE and MKG), U01 DK119085 (IP, RS, MTC).

PMID:36454035 | DOI:10.7554/eLife.79543

Medicine (Baltimore). 2022 Nov 25;101(47):e31877. doi: 10.1097/MD.0000000000031877.

ABSTRACT

BACKGROUND: At present, apart from lung transplantation, no drugs can effectively treat idiopathic pulmonary fibrosis (IPF). Therefore, it is imperative to explore new drugs to control or treat it. Traditional Chinese medicine (TCM) injections have been widely used in the field of IPF, but there is no comparison of their efficacy in the assisted improvement of IPF. Therefore, the purpose of this study is to network meta-analyze the efficacy and safety of 4 kinds of commonly used TCM injections assisted by conventional treatment to improve the disease.

METHODS: Used a computer to find the Randomized Controlled Trials (RCTs) from the 8 major databases (PubMed, EMbase, CENTRAL, MEDLINE, CBM, China National Knowledge Infrastructure, WanFang Database and VIP Chinese Science). Cochrane's risk assessment tool was used to evaluate the quality of the literature. The Grading of Recommendations Assessment, Development and Evaluation approach served to assess the certainty in the evidence of direct and indirect estimates. Revman5.3 (Review Manager (RevMan) Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.) and stata14.0 (Stata/SE 14.0 for Windows (64-bit). Revision Apr 22, 2015.Copyright 1985-2015 StataCorp LP). were used for Statistical analysis. Registration number: CRD42020220570.

RESULTS: After layer-by-layer screening, 20 RCTs were finally included, which include a total of 1363 patients and 4 kinds of RCT of TCM injection (12 studies on Danhong injection, 5 studies on Ligustrazine injection, 2 studies on Huangqi injection and 1 study on Dazhu hongjingtian injection). The results showed: Clinical effective rate: Danhong Injection (Odds ratio [OR] = 3.94, 95% CI [2.34, 6.64], moderate certainty of evidence), Huangqi injection (OR = 3.40, 95% CI [1.38, 8.41], moderate certainty of evidence) and Ligustrazine injection (OR = 2.74, 95% CI [1.62, 4.64], moderate certainty of evidence) combined with conventional treatment had better curative efficacy than that of the conventional treatment group. SUCRA Ranking: Danhong (80.5) > Huangqi (68.5) > Ligustrazine (52.9) > Dazhu hongjingtian (44.3) > Conventional treatment (3.8); Forced Expiratory Volume In 1s/Forced vital capacity%: SUCRA Ranking: Danhong (80.0) > Ligustrazine (62.9) > Conventional treatment (2.1); Carbon monoxide diffusing capacity%: SUCRA Ranking: Ligustrazine (89.9) > Dazhu hongjingtian (63.4) > Danhong (44.9) > Conventional treatment (1.8); Partial pressure of Oxygen: SUCRA Ranking: Dazhu Hongjingtian (87.1) > Danhong (78.8) > Ligustrazine (34.0) > Conventional treatment (0.0); Partial pressure of carbon dioxide: SUCRA Ranking: Danhong (99.3) > Ligustrazine (50.3) > Conventional treatment (0.4). No obvious adverse reactions were found in all studies.

CONCLUSION: The four TCM injections combined with conventional treatment can effectively improve the clinical indicators of patients with IPF, and the improvement effect of Danhong injection was more obvious.

PMID:36451506 | DOI:10.1097/MD.0000000000031877